Schrodinger, Inc. (NASDAQ:SDGR) shares are trading higher on Tuesday. The company disclosed a research collaboration and ...

Hidradenitis suppurativa (HS) is a relatively common skin disease, affecting as many as one percent of people worldwide. But ...

Schrödinger Inc.’s stock soared 14% Tuesday to put in on track for its biggest one-day gain in a year, after the company said ...

Schrödinger today announced a multi-target collaboration and expanded software licensing agreement with Novartis.

Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

Schrodinger (SDGR) today announced a research collaboration and license agreement with Novartis (NVS) to advance multiple development ...

Schrödinger (NASDAQ:SDGR) shares traded higher on Tuesday despite reporting lower-than-expected Q3 2024 financials after the ...

THE Philippine Press Institute (PPI) has spearheaded a health reporting workshop to help local journalists gain a deeper ...

Cellares, the world's first Integrated Development and Manufacturing Organization (IDMO), and a leader in automated cell therapy manufacturing, has appointed Ossama Eissa, former executive at Novartis ...

Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the third quarter of 2024 and provided a business update. In a separate press release issued earlier ...

Analyst Brendan Smith from TD Cowen maintained a Buy rating on Schrodinger (SDGR – Research Report) and keeping the price target at ...

Since the 2023 financing round, Flare’s lead program FX-909 has moved into a phase 1 clinical trial for patients with ...